Replies to post #99758 on Biotech Values

[zipjet]

Only disadvantage that I see is that it might make the FDAmore eager to approve Teva's offering.

Logical and reasonable - as always.

:-)

An inference from that reasonable and logical statement is that Sandoz thinks TEVA's L is not approvable. If they thought it a close call they would not want to push the FDA.

ij

[biomaven0]

That should of course be "authorized generic" not "branded generic" - my Maxalt hasn't kicked in yet. :)

Peter